Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P. Treon, Jorge J. Castillo, Amanda Kofides et al.|Journal of Clinical Oncology|2020Cited by 165
<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinibJorge J. Castillo, Steven P. Treon, Lian Xu et al.|British Journal of Haematology|2019Cited by 103
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomasManit Munshi, Guang Yang, Xia Liu et al.|Blood Cancer Journal|2020Cited by 45
CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemiaJoshua Gustine, Jorge J. Castillo, Lian Xu et al.|Blood Advances|2019Cited by 39
Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom MacroglobulinemiaJorge J. Castillo, Steven P. Treon, Joshua Gustine et al.|Blood|2018Cited by 38